In the trial, 41.7 percent of patients who received the drug combination were cured at the transition of care point. The trial included 15 patients at 12 locations in nine different countries.
The antibiotic is a combination of aztreonam and avibactam and could be used to treat serious bacterial infections that are resistant to most other drug therapy combinations.
As the growth of drug-resistant bacteria continues to rise across the globe, Pfizer;’s new combination could be one that holds promise of improved, life-saving outcomes for patients in need.
“We believe these data demonstrate that [aztreonam and avibactam], if approved, could be an important treatment option for patients with life-threatening bacterial infections that are resistant to almost all currently available antibiotics,” James Rusnak, senior vice president and chief development officer, internal medicine, anti-infectives and hospital for Pfizer said in a statement. “We are committed to meeting this critical need and helping to address the global health threat of antimicrobial resistance.”
The aztreonam-avibactam combination is being developed in partnership with Chicago-based AbbVie. Next, the company will likely seek FDA-approval of the drug.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
